ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to KnowZacks Investment Research • 06/10/26
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026GlobeNewsWire • 06/03/26
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular DiseaseBenzinga • 05/11/26
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMGGlobeNewsWire • 05/08/26
Argenx Obliterates Profit Expectations On 'Solid Print' For Its Immunology PowerhouseInvestors Business Daily • 05/07/26
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive OfficerGlobeNewsWire • 05/06/26
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026GlobeNewsWire • 04/30/26
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDPGlobeNewsWire • 04/18/26
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and EfficiencyBusiness Wire • 03/24/26
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of PipelineGlobeNewsWire • 03/06/26